AdvisorShares Investments LLC Boosts Stock Position in Bright Minds Biosciences Inc. (NASDAQ:DRUG)
AdvisorShares Investments LLC Boosts Stock Position in Bright Minds Biosciences Inc. (NASDAQ:DRUG)
AdvisorShares Investments LLC lifted its position in Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) by 115.5% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 206,716 shares of the company's stock after buying an additional 110,774 shares during the quarter. AdvisorShares Investments LLC's holdings in Bright Minds Biosciences were worth $314,000 at the end of the most recent quarter.
据Holdings Channel.com报道，今年第一季度，AdvisorShares Investments LLC将其在光明心灵生物科学公司(Bright Minds Biosciences Inc.)的持仓提高了115.5%。该机构投资者在本季度额外购买了110,774股后，持有该公司206,716股股票。截至最近一个季度末，AdvisorShares Investments LLC在Bright Minds Biosciences持有的股份价值31.4万美元。
Separately, Checchi Capital Advisers LLC acquired a new position in Bright Minds Biosciences during the 4th quarter worth $45,000. Institutional investors own 7.70% of the company's stock.
另外，Checchi Capital Advisers LLC在第四季度收购了Bright Minds Biosciences的一个新头寸，价值4.5万美元。机构投资者持有该公司7.70%的股份。
Bright Minds Biosciences Price Performance
Bright Minds生物科学的价格表现
DRUG opened at $0.91 on Friday. Bright Minds Biosciences Inc. has a 12 month low of $0.75 and a 12 month high of $8.95. The business has a fifty day moving average price of $0.93 and a 200 day moving average price of $1.40.
周五，毒品的开盘价为0.91美元。Bright Minds Biosciences Inc.的股价为0.75美元的12个月低点，以及8.95美元的12个月高位。该业务的50日移动平均价为0.93美元，200日移动平均价为1.40美元。
About Bright Minds Biosciences
关于Bright Minds生物科学
(Get Rating)
(获取评级)
Bright Minds Biosciences Inc, a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
Bright Minds Biosciences Inc是一家临床前生物科学公司，开发5-羟色胺(5-HT)药物，以改善严重和改变生活的疾病患者的生活。该公司的选择性5-羟色胺受体激动剂组合包括5-HT2C、5-HT2A和5-HT2C/A，用于治疗癫痫、疼痛和神经精神病学。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Bright Minds Biosciences (DRUG)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- Why Apple Could Be At All-Time Highs By Year End
- 免费获取StockNews.com关于Bright Minds生物科学(药物)的研究报告
- MarketBeat：回顾中的一周8/1-8/5
- 如何利用高贝塔系数股票最大化你的投资利润
- 克罗诺斯集团(Cronos Group Inc.)营收上升，是时候收购了吗？
- Beyond Meat不是没有希望，而且它很便宜
- 苹果为何可能在年底创下历史新高
Want to see what other hedge funds are holding DRUG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating).
想看看还有哪些对冲基金持有毒品吗？访问HoldingsChannel.com获取光明心灵生物科学公司(Bright Minds Biosciences Inc.)最新的13F备案文件和内幕交易(纳斯达克：毒品获取评级)。
Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Bright Minds生物科学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Bright Minds Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。